Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

RAAZI CLINICAL LABORATORY LLC.

NPI: 1245838671 · HOUSTON, TX 77095 · Clinical Medical Laboratory · NPI assigned 10/16/2020

$721K
Total Medicaid Paid
36,756
Total Claims
20,050
Beneficiaries
41
Codes Billed
2021-11
First Month
2024-12
Last Month

Provider Details

Authorized OfficialHAIDARI, MEHRAN (LABORATRY DIRECTOR)
NPI Enumeration Date10/16/2020

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2021 448 $14K
2022 4,114 $106K
2023 30,110 $561K
2024 2,084 $39K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 2,065 928 $108K
80323 2,123 953 $70K
80361 2,106 937 $58K
80346 2,106 937 $45K
80364 2,106 937 $44K
80345 2,103 935 $42K
80358 1,859 775 $42K
80336 2,123 953 $41K
80370 2,106 937 $40K
80325 2,106 937 $36K
80353 2,106 937 $34K
U0004 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r 607 545 $32K
83992 2,105 936 $28K
80321 1,878 791 $22K
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism 1,291 1,039 $21K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 611 545 $14K
87481 941 763 $8K
87640 1,012 823 $6K
87500 972 795 $5K
87653 1,013 824 $5K
87651 Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe 1,013 824 $5K
87641 858 704 $4K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 296 255 $3K
80356 227 145 $3K
87631 78 75 $1K
80359 227 145 $1K
87529 72 61 $1K
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe 66 61 $988.00
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe 66 61 $988.00
87563 66 61 $970.00
87486 80 77 $392.98
87541 79 76 $364.91
87581 79 76 $364.91
87498 79 76 $364.91
87511 42 37 $259.84
87661 Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe 25 25 $235.84
80338 13 13 $0.00
80366 13 13 $0.00
80355 13 13 $0.00
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 12 12 $0.00
80333 13 13 $0.00